ESC Premium Access

Targeting PCSK9 in clinical practice: guidance and future.

Topic: Lipids
Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Amgen and Sanofi-Regeneron

Presentation

About the speaker

Professor John Kastelein

University of Amsterdam, Amsterdam (Netherlands (The))
20 presentations
1 follower

4 more presentations in this session

Introduction - PCSK9 inhibition: science, outcomes and guidance.

Speaker: Professor P. Barter (Sydney, AU) Professor J. Kastelein (Amsterdam, NL)

Thumbnail

PCSK9 as target for treatment: the genetic validation.

Speaker: Professor B. Ference (Cambridge, GB)

Thumbnail

Novel PCSK9 outcomes in perspective: lessons from FOURIER & ODYSSEY.

Speaker: Doctor J. Robinson (Iowa, US)

Thumbnail

Discussion and summary - PCSK9 inhibition: science, outcomes and guidance

Speaker: Professor P. Barter (Sydney, AU)

Thumbnail

Access the full session

PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)

Speakers: Professor J. Kastelein, Professor P. Barter, Professor J. Kastelein, Professor B. Ference, Doctor J. Robinson...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk